The question that should concern compliance teams
Two patented pharmaceutical products can share the same tariff classification and the same country of origin. Yet under current US policy, they may not receive the same tariff treatment. One product may be covered by an approved investment and pricing agreement between its company and the US Government. The other may not.
The practical point for compliance teams is this: the tariff may no longer be determined solely by the goods. It may also depend on the company for which the goods are imported, and whether that company is covered by an approved plan or agreement.
Manufacturing identity remains important to that question, but it is not necessarily the only corporate relationship that matters. The agreements can also turn on ownership, supply arrangements and the importer of record. That distinction runs through the rest of this article.
What the United States has introduced
The mechanism sits within the Section 232 pharmaceutical tariff framework, set out in a presidential proclamation and refined through company-specific agreements since. Its rate structure works by coordination with the ordinary duty rate, not by simple addition:
Covered patented pharmaceutical articles are generally subject to a total ad valorem tariff rate of 100 percent under the measure. Lower rates can apply according to origin, approved onshoring plans, company-specific agreements and specified product exclusions. The additional Section 232 duty is calculated so that, together with the ordinary Column 1 duty, it produces the applicable rate set out in the proclamation. Anti-dumping, countervailing and other trade remedies can continue to apply separately, as with other Section 232 measures.
The tiers
- A 20 percent combined rate can apply to products from companies with a Secretary-approved US onshoring plan. That rate is scheduled to rise to 100 percent on 2 April 2030.
- A 15 percent combined ceiling applies to qualifying products from the EU, Japan, South Korea, Switzerland and Liechtenstein, subject to the detailed rules of each arrangement.
- The United Kingdom has its own tier: a 10 percentage point addition, reducing to zero to the extent required by a future US-UK pharmaceutical pricing agreement.
- A zero Section 232 rate, until 20 January 2029, can apply to eligible companies that also enter into most-favoured-nation pharmaceutical pricing agreements with the US Government. Zero means no additional Section 232 duty; the ordinary HTSUS rate and any other applicable charges are not automatically removed.
- Generic pharmaceutical articles and their associated ingredients, including qualifying biosimilar products, are not currently subject to the Section 232 tariffs. Their treatment is subject to future review.
- For companies not covered by the earlier implementation date, the relevant tariff treatment begins on 29 September 2026.
What counts as a patented pharmaceutical article
The proclamation and its annexes define this precisely rather than commercially. A patented pharmaceutical article is one that is subject to a valid, unexpired US patent and is listed in the FDA's Orange Book (for drugs) or Purple Book (for biologics), together with its active pharmaceutical ingredients and key starting materials. That is the definition a compliance team needs to capture in product-master data, not a looser working assumption of what counts as "patented".
How the treatment is administered
The tiers are implemented through specific HTSUS Chapter 99 headings. The main ones a compliance team will meet are:
- 9903.04.60 - the general patented-pharmaceutical rate
- 9903.04.62 - the rate for the EU, Japan, South Korea, Switzerland and Liechtenstein
- 9903.04.63 - the United Kingdom rate
- 9903.04.64 - the rate for approved onshoring plans
- 9903.04.65 - the rate for onshoring plans combined with MFN pricing agreements
The annexes also carry further headings for categories such as orphan drugs, certain early-mover companies and generics. Knowing which heading applies to a given entry is what turns this from general awareness into a working compliance control.
The proclamation also authorises the US Government to reimpose Section 232 tariffs, both prospectively and retroactively, where a company is found to have committed fraud or deliberately misrepresented its onshoring commitments. That is distinct from the more routine risk that a company simply falls out of compliance with the conditions of its agreement, which would be expected to result in reversion to the standard rate through the normal government review process rather than retroactive penalties. Both risks matter to compliance planning and are addressed further below.
The nine latest agreements
On 31 August 2026, the White House announced most-favoured-nation pricing agreements with nine further pharmaceutical manufacturers: Alcon, Astellas, BeOne Medicines, BridgeBio, CSL, Kyowa Kirin, Sun Pharma, Teva, UCB. Together, the nine companies committed at least USD 19.6 billion to US manufacturing. Several also agreed to contribute active pharmaceutical ingredients to the US Strategic Active Pharmaceutical Ingredients Reserve.
An important evidential distinction
The 31 August White House fact sheet describes pricing, investment and supply commitments, but does not specify the tariff treatment granted to each company individually. Global Trade Alert (GTA), an independent monitor of trade-policy interventions, separately records tariff relief associated with individual agreements, including BeOne Medicines. Importers should therefore verify the relevant agreement, HTSUS provision and CBP instructions before claiming company-specific treatment.
Why traditional tariff-master data may no longer be enough
The established customs model asks a settled set of questions: What is the product? What is its tariff classification? Where does it originate? What is its customs value? Are preferential or additional duties applicable?
Company-specific treatment adds a further layer that most customs-master-data systems are not built to hold. In practical terms: customs master data has traditionally described the product and the transaction. It may now also need to describe the product's relationship to a specific company, government agreement and continuing corporate commitment:
- Who manufactured the product, and for which company was it imported?
- Which legal entity owns or supplies it?
- Is that company named in an agreement or annex?
- Are subsidiaries, affiliates and contract manufacturers covered?
- Does the treatment apply to every product the company makes, or only specified products?
- Was the agreement in effect when the goods entered, or were withdrawn from warehouse?
- Has the company continued to meet its pricing, reporting and investment obligations?
Where compliance failures could arise
- Applying preferential treatment to an affiliate that is not covered by the agreement
- Confusing brand ownership with manufacturing responsibility
- Failing to distinguish patented products from generics or biosimilars
- Relying on a supplier declaration without supporting legal evidence
- Missing changes to government annexes or CBP instructions
- Using an outdated duty rate in ERP or broker systems
- Failing to retain evidence supporting the company-specific treatment claimed
- Incorrectly applying treatment to goods held in a foreign-trade zone
- Overlooking the possibility of duties being reimposed
Two distinct risks sit behind that last point. Ordinary non-compliance with agreed conditions would be expected to lead to reversion to the standard rate through the government's normal review process. Fraud or deliberate misrepresentation of onshoring commitments is different in kind: it can trigger prospective and retroactive reimposition of tariffs, alongside other possible penalties. For any business relying on a company-specific rate, that second risk is a material financial and audit exposure, not a theoretical one.
Eight actions for compliance teams
- Identify all pharmaceutical products potentially covered by the Section 232 measure.
- Separate patented products from generics, biosimilars and exempt specialty products.
- Record the actual manufacturer, the importing company, and the responsible legal entity for each product.
- Check company eligibility against official annexes, Commerce decisions and CBP guidance.
- Confirm that subsidiaries and contract manufacturers fall within the stated scope.
- Update customs, ERP and broker instructions with the correct HTSUS Chapter 99 heading, effective dates and supporting references.
- Retain evidence supporting every claim to reduced or zero tariff treatment.
- Create a monitoring and contingency process for suspension, withdrawal or retrospective reimposition.
The wider lesson beyond pharmaceuticals
Customs is increasingly becoming an instrument of industrial, investment and national-security policy. Governments can use tariff relief as an incentive for local production, pricing concessions and supply-chain commitments. A customs decision may consequently depend on information held by legal, public-affairs, procurement or corporate-strategy teams, not only by customs and trade functions. Compliance functions will need stronger internal data connections and clearer ownership of government agreements.
ECTM presents this as a possible model for future measures in other sectors, not as a certainty that it will spread. The pharmaceutical framework is, at present, the clearest working example of company-specific tariff treatment. Whether it becomes a template elsewhere is a question worth watching, not one that can yet be answered.
For ECTM, the practical opportunity sits in exactly this data-governance gap: helping clients redesign tariff and product-master data, map manufacturer and corporate-entity relationships, monitor agreements and effective dates, govern broker instructions, build evidence and audit trails, and plan for the contingency of withdrawn treatment. That is advisory territory ECTM is well placed to occupy.
Conclusion
Classification, origin and value remain fundamental to customs compliance. But they may no longer tell the whole story. Where governments negotiate company-specific tariff treatment, compliance teams must understand not only what is being imported, but who produced it, which legal entity is covered, and whether the underlying conditions remain satisfied. The tariff has become part customs rule, part corporate agreement and part industrial policy.
